R N Tamura

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi An examination of the efficiency of the sequential parallel design in psychiatric clinical trials
    Roy N Tamura
    Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Clin Trials 4:309-17. 2007
  2. ncbi Comparing time to onset of response in antidepressant clinical trials using the cure model and the Cramer-von Mises test
    R N Tamura
    Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Stat Med 19:2169-84. 2000
  3. ncbi Estimation of treatment effect for the sequential parallel design
    Roy N Tamura
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Stat Med 30:3496-506. 2011
  4. ncbi Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group
    D Michelson
    Medical University of South Carolina, Charleston, USA
    Am J Psychiatry 155:1570-7. 1998
  5. ncbi Score tests for dose effect in the presence of non-responders
    Xiaohui Luo
    Department of Statistics, North Carolina State University, Raleigh, NC 27695 8203, USA
    Stat Med 23:3581-91. 2004

Detail Information

Publications5

  1. ncbi An examination of the efficiency of the sequential parallel design in psychiatric clinical trials
    Roy N Tamura
    Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Clin Trials 4:309-17. 2007
    ..Because of this high failure rate, a novel clinical trial design has been proposed which incorporates a second phase in which non-responders to placebo are randomly reassigned to drug or placebo...
  2. ncbi Comparing time to onset of response in antidepressant clinical trials using the cure model and the Cramer-von Mises test
    R N Tamura
    Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Stat Med 19:2169-84. 2000
    ..Results of the simulation study suggest that for common designs and sample sizes used in such trials, the statistic has reasonable size and power properties as long as censoring is moderate...
  3. ncbi Estimation of treatment effect for the sequential parallel design
    Roy N Tamura
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Stat Med 30:3496-506. 2011
    ..The potential gains appear to be greatest in moderate-sized trials, which would typically be the case in phase II trials...
  4. ncbi Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group
    D Michelson
    Medical University of South Carolina, Charleston, USA
    Am J Psychiatry 155:1570-7. 1998
    ..The authors studied the efficacy of fluoxetine treatment in panic disorder and measured the relative contributions of changes in symptoms to overall improvement...
  5. ncbi Score tests for dose effect in the presence of non-responders
    Xiaohui Luo
    Department of Statistics, North Carolina State University, Raleigh, NC 27695 8203, USA
    Stat Med 23:3581-91. 2004
    ..Extensive simulations establish the power properties of the tests and show that our proposed score test has the best performance. The approach is illustrated by a multi-country clinical trial of rapid acting Intramuscular Olanzapine...